IMV (OTCMKTS:IMVIQ) & Bio-Path (NASDAQ:BPTH) Financial Analysis

Institutional and Insider Ownership

5.7% of Bio-Path shares are owned by institutional investors. 0.7% of Bio-Path shares are owned by insiders. Comparatively, 0.3% of IMV shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Bio-Path and IMV’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Bio-Path	N/A	-2,842.40%	-337.48%
IMV	N/A	N/A	N/A

Valuation & Earnings

This table compares Bio-Path and IMV”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bio-Path	N/A	N/A	-$16.08 million	($1.09)	-0.03
IMV	$330,000.00	0.00	-$37.99 million	($4.59)	N/A

Bio-Path has higher earnings, but lower revenue than IMV. Bio-Path is trading at a lower price-to-earnings ratio than IMV, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Bio-Path has a beta of -0.39, suggesting that its share price is 139% less volatile than the S&P 500. Comparatively, IMV has a beta of 0.9, suggesting that its share price is 10% less volatile than the S&P 500.

Summary

IMV beats Bio-Path on 5 of the 9 factors compared between the two stocks.

About Bio-Path

Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing BP1001-A that is in Phase I clinical trial for the treatment of solid tumors; Liposomal Bcl-2 (BP1002), which is in Phase I clinical trial for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; and Liposomal STAT3 (BP1003) for treating pancreatic cancer, non-small cell lung cancer, and AML. The company was founded in 2007 and is based in Bellaire, Texas.

About IMV

IMV Inc. operates as a clinical-stage immuno-oncology company. The company develops a portfolio of therapies based on DPX its immune-educating technology platform for treatment of solid and hematological cancers. The company's lead drug candidate includes maveropepimut-S, a DPX-based immunotherapy that targets survivin-expressing cells that is Phase II clinical trials for diffuse large B cell lymphoma; ovarian cancer; and bladder, liver, and MSI-H solid tumors, as well as in Phase I clinical trial for breast cancer. It also develops DPX-SurMAGE that is in Phase I clinical trial for bladder cancer; and DPX-COVID-19 and DPX-RSV for infectious diseases. The company was formerly known as Immunovaccine Inc. and changed its name to IMV Inc. in May 2018. IMV Inc. was founded in 2000 and is headquartered in Dartmouth, Canada.